title: The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
abstract: Cancer stem cells (CSCs) are thought to be responsible for tumor progression, metastasis, and recurrence. HER2 overexpression is associated with increased CSCs, which may explain the aggressive phenotype and increased likelihood of recurrence for HER2(+) breast cancers. Telomerase is reactivated in tumor cells, including CSCs, but has limited activity in normal tissues, providing potential for telomerase inhibition in anti-cancer therapy. The purpose of this study was to investigate the effects of a telomerase antagonistic oligonucleotide, imetelstat (GRN163L), on CSC and non-CSC populations of HER2(+) breast cancer cell lines. The effects of imetelstat on CSC populations of HER2(+) breast cancer cells were measured by ALDH activity and CD44/24 expression by flow cytometry as well as mammosphere assays for functionality. Combination studies in vitro and in vivo were utilized to test for synergism between imetelstat and trastuzumab. Imetelstat inhibited telomerase activity in both subpopulations. Moreover, imetelstat alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC functional ability, as shown by decreased mammosphere counts and invasive potential. Tumor growth rate was slower in combination-treated mice compared to either drug alone. Additionally, there was a trend toward decreased CSC marker expression in imetelstat-treated xenograft cells compared to vehicle control. Furthermore, the observed decrease in CSC marker expression occurred prior to and after telomere shortening, suggesting that imetelstat acts on the CSC subpopulation in telomere length-dependent and -independent mechanisms. Our study suggests addition of imetelstat to trastuzumab may enhance the effects of HER2 inhibition therapy, especially in the CSC population.
authors: Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
authors: Jillian E
authors: JE
authors: Koziel
authors: Brittney-Shea
authors: BS
authors: Herbert
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D051379:Mice; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D009841:Oligonucleotides; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D019098:Telomerase / Q000037:antagonists & inhibitors; D016615:Telomere / Q000187:drug effects; D000068878:Trastuzumab; D023041:Xenograft Model Antitumor Assays
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004791:Enzyme Inhibitors; D007211:Indoles; D009536:Niacinamide; D009841:Oligonucleotides; D018719:Erb-b2 Receptor Tyrosine Kinases; D019098:Telomerase; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C519562:imetelstat
references: Breast Cancer Res. 2006;8(5):R59
references: 17062128
references: J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85
references: 17179479
references: Nat Protoc. 2006;1(3):1583-90
references: 17406450
references: Nucleosides Nucleotides Nucleic Acids. 2007;26(10-12):1577-9
references: 18066830
references: Curr Protoc Cell Biol. 2003 Nov;Chapter 18:Unit 18.6
references: 18228424
references: J Cell Biochem. 2008 May 15;104(2):444-52
references: 18044713
references: J Natl Cancer Inst. 2008 May 7;100(9):672-9
references: 18445819
references: Cell. 2008 May 16;133(4):704-15
references: 18485877
references: Curr Opin Genet Dev. 2008 Feb;18(1):48-53
references: 18356041
references: Leukemia. 2008 Jul;22(7):1410-8
references: 18449204
references: PLoS One. 2008;3(8):e2888
references: 18682804
references: Nat Rev Cancer. 2008 Oct;8(10):755-68
references: 18784658
references: Oncogene. 2008 Oct 16;27(47):6120-30
references: 18591932
references: Cell Stem Cell. 2007 Nov;1(5):555-67
references: 18371393
references: Cancer Res. 2008 Dec 15;68(24):10377-86
references: 19074907
references: Cancer Res. 2009 Feb 15;69(4):1302-13
references: 19190339
references: Clin Cancer Res. 2009 Mar 15;15(6):2010-21
references: 19276287
references: Mol Cancer Ther. 2009 Jul;8(7):2027-35
references: 19509275
references: Cell. 2009 Aug 21;138(4):645-59
references: 19682730
references: Breast Cancer Res Treat. 2009 Nov;118(1):21-32
references: 18853252
references: Clin Cancer Res. 2010 Jan 1;16(1):154-63
references: 20048334
references: Int J Cancer. 2010 Jul 15;127(2):321-31
references: 19908230
references: Mol Cancer Ther. 2010 Jun;9(6):1489-502
references: 20501798
references: PLoS One. 2010;5(9). pii: e12487. doi: 10.1371/journal.pone.0012487
references: 20824134
references: Cancer Res. 2010 Nov 15;70(22):9494-504
references: 21062983
references: Clin Cancer Res. 2011 Jan 1;17(1):111-21
references: 21208905
references: Cancer Res. 2011 Aug 1;71(15):5317-26
references: 21685475
references: Int J Oncol. 2013 May;42(5):1709-15
references: 23545855
references: Cancer Treat Rev. 2013 Aug;39(5):444-56
references: 22841437
references: Cancer Res. 2013 Jun 15;73(12):3489-93
references: 23740771
references: Cancer Res. 2013 Sep 15;73(18):5821-33
references: 23832666
references: Adv Enzyme Regul. 1984;22:27-55
references: 6382953
references: J Cell Sci. 1989 Mar;92 ( Pt 3):513-8
references: 2592453
references: Science. 1994 Dec 23;266(5193):2011-5
references: 7605428
references: Nucleic Acids Res. 1995 Sep 25;23(18):3794-5
references: 7479015
references: Science. 1998 Jan 16;279(5349):349-52
references: 9454332
references: Genes Dev. 1999 Sep 15;13(18):2388-99
references: 10500096
references: J Clin Oncol. 2005 Jun 1;23(16):3676-85
references: 15738535
references: Cancer Res. 2005 Jul 1;65(13):5506-11
references: 15994920
references: Oncogene. 2005 Aug 4;24(33):5262-8
references: 15940257
references: Cancer Res. 2005 Sep 1;65(17):7866-73
references: 16140956
references: Hepatology. 2005 Nov;42(5):1127-36
references: 16114043
references: Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6
references: 16488983
references: Clin Cancer Res. 2006 May 15;12(10):3184-92
references: 16707619
references: Eur J Cancer. 2006 Jun;42(9):1197-203
references: 16644207
references: Genes Dev. 2013 Oct 15;27(20):2192-206
references: 24142872
references: PLoS One. 2014;9(1):e85155
references: 24409321
references: Stem Cell Reports. 2014 Jan 14;2(1):78-91
references: 24511467
references: Breast Cancer Res. 2008;10(2):R25
references: 18366788
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Oncogene. 2002 Jan 21;21(4):638-42
references: 11850790
references: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references: 12629218
references: J Biol Chem. 2003 Jun 13;278(24):21631-8
references: 12690099
references: Cancer Res. 2003 Jul 15;63(14):3931-9
references: 12873987
references: Cancer Chemother Pharmacol. 2004 Feb;53(2):186-90
references: 14605867
references: Clin Cancer Res. 2006 Oct 1;12(19):5615-21
references: 17020963
references: Nat Rev Drug Discov. 2006 Jul;5(7):577-84
references: 16773071
references: Mol Cell. 2004 May 21;14(4):501-13
references: 15149599
references: Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):897-905
references: 17175117